Clinical trials concerning medicinal products | Italian Medicines Agency

Clinical trials concerning medicinal products |
Italian Medicines Agency
Aifa toggle bar Search
Search keywords
The Agency
The Agency
Mission and values
Organisation
Scientific and Economic Committee for Medicines
Support and Coordination Secretariats and Advisory Committees
International Collaborations
EU Projects
Legislation
Forms
Competition notices
Resolutions
Tenders and contracts
Quality assurance
Guarantee Committee
Atti di notifica
Associazioni dei pazienti
AIFA Incontra
Contacts
Certified email
COVID-19
COVID-19
Communications about COVID-19
COVID-19 Vaccines
Medicines usable for treatment of COVID-19 disease
Use of monoclonal antibodies for COVID-19
Use of antivirals for COVID-19
Monitoring of medicinal products used during the COVID-19 epidemic
Clinical Trials - COVID-19
Compassionate Use Programs - COVID-19
Access to medicinal products
Access to medicinal products
Early access and off-label use
Authorisation of medicinal products
Medicine shortages
Antibiotic medicinal products
Biological medicinal products
Vaccines
Blood derivatives
Generic medicinal products
Biosimilar medicinal products
Orphan medicinal products
Advanced therapies
Homeopathic medicinal products
Allergens
Medicinali di origine vegetale
Ancillary medicinal substances incorporated in medical devices
Safety of medicinal products
Safety of medicinal products
Pharmacovigilance
National Pharmacovigilance Network
Adverse Reactions to medicinal products
Persons in charge of Pharmacovigilance
European Eudravigilance System
Accesso alle segnalazioni - ADRreports
Regional pharmacovigilance funds
Segnali di sicurezza
Risk management measures
Medicinal products subject to additional monitoring
Quality and Inspections
Quality and Inspections
Quality defects
Inspections and authorisations
Qualified person
Fight of pharmaceutical crime
Research and Clinical trials
Research and Clinical trials
Clinical trials concerning medicinal products
EU Regulation on Clinical trials
National Observatory on Clinical Trials
Registro Studi Osservazionali
Comitati Etici Nazionali (CEN)
Ethics Committees Coordination Centre
Independent clinical research
Mappa dei centri di Sperimentazione Clinica
Pricing and reimbursement
Pricing and reimbursement
Negotiation and reimbursement
Economic evaluations
Monitoring Registers
AIFA Notes
Lists of Class A and Class H medicinal products
Innovative medicinal products
Transparency Lists
Consumption and pharmaceutical expenditure
Consumption and pharmaceutical expenditure
The Medicines Utilization Monitoring Centre (OsMed)
Governance of pharmaceutical expenditure
Monitoring pharmaceutical expenditure
Innovation and planning
Innovation and planning
Innovation and scientific advice
Horizon scanning
Information and communication
Information and communication
FarmaciLine
Medical and scientific information
FAQ
Publications
Communication campaigns
Eventi AIFA
Scientific Seminars
Press releases
Dossier AIFA
Mobile APP AIFA
APP Firstline AIFA - Antibiotici
ABC della Ricerca Clinica
Presentations and speeches
Public consultations and documents
Documents shared with scientific communities
Calendario eventi
Archivio
AIFA data
AIFA data
OsMed Data
Open Data
Companies Section
Companies Section
Requests for authorisation of conferences and meetings
Payment of fees and annual duties
MA Electronic invoicing
Application for reimbursement and pricing
Access information
Notifica concessionari di vendita
Comunicazione prima commercializzazione
Open governance
Open governance
Disposizioni Generali
Organizzazione
Consulenti e collaboratori
Personale
Bandi di Concorso
Performance
Enti controllati
Attività e procedimenti
Provvedimenti
Bandi di gara e contratti
Sovvenzioni, contributi, sussidi, vantaggi economici
Bilanci
Beni immobili e gestione patrimonio
Controlli e rilievi sull'Amministrazione
Servizi Erogati
Pagamenti dell'Amministrazione
Opere pubbliche
Pianificazione e governo del territorio
Informazioni ambientali
Interventi straordinari di emergenza
Altri Contenuti
Clinical trials concerning medicinal products
Clinical trials concerning medicinal products
Clinical trials means any human study aimed at detecting or verifying the effects of a new medicine or of an existing medicine tested for a new therapeutic use, in order to establish its safety or efficacy. The trial is divided into several phases and is carried out first in laboratory and on animal models (pre-clinical trial) and then on humans (clinical trial).
Pre-clinical trial
This phase allows to observe the behaviour and the level of toxicity of the molecule on a complex living organism: what is its route of administration, how it is absorbed and subsequently eliminated.
At the beginning, “in vitro” studies are carried out in order to understand the characteristics of the
substance
from which a medicine is likely to be obtained.  The substance is placed in a test tube together with cell cultures or microorganisms and a series of tests is carried out in highly specialised laboratories.
Only once laboratory tests have established that the molecule has potential therapeutic effects, animal testing can be initiated. The purpose of “in vivo” studies is to verify whether the efficacy of the active substance demonstrated “in vitro” is confirmed in specific animal models of human diseases. These studies also aim to provide preliminary data on the behaviour of the investigational molecule - once it is introduced in the body - in terms of absorption, intra-tissue distribution, metabolism and excretion (pharmacokinetics), as well as to demonstrate its actual safety before human testing is initiated (toxicology).
Clinical trials
Phase 1
In Phase 1 studies, the active substance is tested in humans. The aim is to provide an initial assessment of the safety and tolerability of the medicinal product.
These studies are conducted in few selected centres on a limited number of healthy volunteers, who have proved not to have disease predisposition. The main objective is to assess the expected potential side effects, based on the results of previous studies on animals, and to establish how the medicine works and how it is distributed in the body.
Volunteers are divided into several groups. Each group receives a different dose of the medicine, to establish any undesirable effects in relation to the dosage administered. If the trial focuses on serious diseases, studies can be conducted directly on patients who are affected by such diseases and for whom the medicine is being developed.
If the medicine proves to have an acceptable level of toxicity in relation to the expected benefit (benefit/risk profile), the subsequent trial phases can be initiated.
Phase 2
In Phase 2 studies, the therapeutic activity of the potential medicine (i.e. its ability to produce the desired curative effects on the human body) is investigated. This phase also allows to understand the best dosage to be tested in the following phases, and to determine the effect of the medicine in relation to certain parameters (such as blood pressure), which are considered indicative of the patient’s health.
In phase 2 studies, the substance is administered to volunteers who are affected by the disease for which the medicine is being developed.
Subjects enrolled in the study are generally divided into several groups. Each group receives a different dose of the medicine and, when ethically possible, a placebo (a substance lacking therapeutic efficacy). To prevent placebo from affecting participants’ expectations, activity and safety parameters are assessed and the patient (
single-blind study
), or doctor and patient (
double-blind study
) are kept ignorant of the type of treatment received or administered.
This phase lasts about two years and helps to demonstrate the non-toxicity and the activity of the new investigational active substance.
Phase 3
Phase 3 studies allow to determine how effective the medicine is, whether it has any additional benefit compared to similar medicines already on the market, and the relationship between risk and benefit. In this case, the patients enrolled are hundreds or thousands
The efficacy of the medicine on symptoms, quality of life or survival is compared against placebo, other medicines already in use or no treatment.
The type of study used at this stage is the
randomised controlled trial.
This is a type of study in which patients are randomly assigned the new active substance or the control medicine (usually the standard treatment used for the investigated disease) and is very reliable in defining the effectiveness of a medicinal product.
The random assignment of the new medicine or of the control medicine ensures that the two groups have the same characteristics except for the medicinal product taken. Therefore, at the end of the trial, any differences in the participants’ health can be attributed exclusively to the treatment and not to errors or to chance.
During this phase, the onset, frequency and severity of undesirable effects are closely monitored. The duration of administration varies according to the trial objectives, but usually lasts months. The monitoring period of the medicine’s effects is often longer, sometimes reaching 3-5 years.
Phase 4
This is the clinical trial phase that includes studies conducted after the medicinal product has been approved, as part of the approved indications and in full compliance with the Summary of product characteristics (SmPC). It is called “post-marketing surveillance” because it is implemented after the product has entered the market.
During this phase, which may last a few years, additional and new information is acquired and the rarest adverse reactions are evaluated. These are the adverse reactions that could not emerge during clinical trials, but that can be detected with the mass use of the new medicine.
EXPAND ALL
Clinical trial actors
Clinical research in Italy involves many actors: AIFA, for study authorisation and amendments to each phase; the Istituto Superiore di Sanità for consultative opinions on studies and amendments to Phase I; Ethics Committees for opinions within the health facilities where the clinical study is carried out; Directorates General of the health facilities for the definition of contracts; the Eudravigilance network for the reporting of serious and unexpected adverse reactions  during the trials; promoters and researchers directly involved in the conduct of each trial.
Thank to its role in the European network of competent authorities for clinical trials, AIFA coordinates and directs all aspects concerning investigational medicines.
Caselle di posta istituzionali
Di seguito vengono fornite indicazioni per il corretto utilizzo delle caselle di posta AIFA in materia di sperimentazione clinica:
reg.eu.sperimentazioni@aifa.gov.it
: deve essere utilizzata
esclusivamente
per
quesiti sull’applicazione del Regolamento europeo 536/2014
o eventuali
notifiche
relative a sperimentazioni cliniche
in procinto di essere sottomesse
in accordo allo stesso.
CTR@aifa.gov.it
: deve essere utilizzata
esclusivamente
dai
Promotori delle sperimentazioni cliniche sottomesse in CTIS
in merito a specifiche problematiche in tutte le fasi di gestione della sperimentazione in CTIS. Si chiede di indicare nell’oggetto le seguenti informazioni:
EU CT number
, la parte del fascicolo di domanda oggetto di richiesta (Parte I, Parte II o Parte I + Parte II), se
in validazione o in valutazione
Questa casella di posta è infatti utilizzata per scambi di e-mail tra gli Stati Membri su questioni relative a specifici clinical trial sottomessi su CTIS (pubblicata sul sito della Commissione europea: EudraLex - Volume 10 - Clinical trials guidelines,  Chapter V - Additional documents, List of national contact points -
sperimentazione.clinica@aifa.gov.it
: deve essere utilizzata
esclusivamente
per
quesiti
eventuali notifiche
relative a
sperimentazioni cliniche ancora in corso sotto la Direttiva 2001/20/CE
info_rso@aifa.gov.it
: deve essere utilizzata
esclusivamente
per questioni relative a
studi osservazionali
Al fine di ottimizzare la gestione delle richieste, si chiede cortesemente di non inserire come destinatari di una e-mail i sopracitati indirizzi contemporaneamente, né di inviare la medesima e-mail separatamente agli stessi.
Uffici di riferimento
Reference offices
Area Pre-autorizzazione e Ricerca
Paolo Foggi
p.foggi@aifa.gov.it
Ufficio Sperimentazioni Cliniche
Fabrizio Galliccia
f.galliccia@aifa.gov.it
Research and Clinical trials
Clinical trials concerning medicinal products
EU Regulation on Clinical trials
National Observatory on Clinical Trials
Registro Studi Osservazionali
Comitati Etici Nazionali (CEN)
Ethics Committees Coordination Centre
Independent clinical research
Mappa dei centri di Sperimentazione Clinica
Share
Nested Applications
Highlights
21/04/2026 - Medicine Use: 2024 Regional Reports Now Available Online
17/04/2026 - From one-size-fits-all treatments to personalised care: the revolution in precision medicine
TUTTE LE NEWS - IN EVIDENZA
ALL NEWS
News
21/04/2026
Medicine Use: 2024 Regional Reports Now Available Online
15/04/2026
AIFA updates the Transparency Lists
13/04/2026
Medicine Shortage Communication on Endoxan (ciclofosfamide)
All news
Nested Applications
Press
From one-size-fits-all treatments to personalised care: the revolution in precision medicine
All press releases
Last tweets
📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al...
Vai al post →
🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ...
Vai al post →
🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m...
Vai al post →
💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ...
Vai al post →
⚠️ Attenzione alle false cure miracolose

Negli ultimi tempi si sta diffondendo un business pericol...
Vai al post →
#AIFA promuove l’ascolto e la trasparenza
Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Go to Twitter profile
Go to Twitter profile
aifa_ufficiale
Multimedia
Medicina di precisione e appropriatezza prescrittiva
Go to YouTube channel
Cookie Bar
Footer
The agency
Home Page
FarmaciLine
User participation and satisfaction
Citizens' access
Modulistica
Open governance
Acts of notification
Legal notification
TrovaNormeFarmaco
Competition notices
Tenders and contracts
Contacts
Via del Tritone, 181 00187 Roma
Contacts
Certified e-mail (PEC) contacts
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR
FOLLOW US ON
label.button.spotify
Bluesky
FEED RSS
Feed Rss
Cookie management
Sezione Link Utili
Legal notice
Social Media Policy
Dichiarazione di accessibilità
Web accessibility
Website statistics
Online services
go to beginning of content